Shenzhen - Delayed Quote CNY

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ)

9.37
-0.16
(-1.68%)
At close: 3:04:27 PM GMT+8
Loading Chart for 002332.SZ
  • Previous Close 9.53
  • Open 9.28
  • Bid 9.37 x --
  • Ask 9.38 x --
  • Day's Range 9.33 - 9.56
  • 52 Week Range 8.60 - 14.80
  • Volume 14,737,900
  • Avg. Volume 18,343,439
  • Market Cap (intraday) 9.269B
  • Beta (5Y Monthly) 0.21
  • PE Ratio (TTM) 24.03
  • EPS (TTM) 0.39
  • Earnings Date --
  • Forward Dividend & Yield 0.30 (3.15%)
  • Ex-Dividend Date May 28, 2025
  • 1y Target Est 14.43

Zhejiang Xianju Pharmaceutical Co.,Ltd. manufactures and sells steroids and hormones worldwide. The company offers gynecological, anesthesia, respiratory, dermatology, generic drug, and other products; and active pharmaceutical ingredients (API), such as corticosteroids, sex hormone, progesterone, non-hormone series, newchem API, and intermediates products. The company was founded in 1972 and is headquartered in Xianju, China.

www.xjpharma.com

3,205

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002332.SZ

View More

Performance Overview: 002332.SZ

Trailing total returns as of 6/5/2025, which may include dividends or other distributions. Benchmark is 000001.SS (000001.SS) .

YTD Return

002332.SZ
2.63%
000001.SS (000001.SS)
0.96%

1-Year Return

002332.SZ
19.54%
000001.SS (000001.SS)
10.40%

3-Year Return

002332.SZ
13.75%
000001.SS (000001.SS)
5.90%

5-Year Return

002332.SZ
36.66%
000001.SS (000001.SS)
15.47%

Compare To: 002332.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002332.SZ

View More

Valuation Measures

Annual
As of 6/4/2025
  • Market Cap

    9.43B

  • Enterprise Value

    8.13B

  • Trailing P/E

    24.26

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.38

  • Price/Book (mrq)

    1.56

  • Enterprise Value/Revenue

    2.05

  • Enterprise Value/EBITDA

    17.05

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.82%

  • Return on Assets (ttm)

    5.41%

  • Return on Equity (ttm)

    6.34%

  • Revenue (ttm)

    3.97B

  • Net Income Avi to Common (ttm)

    390.04M

  • Diluted EPS (ttm)

    0.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.36B

  • Total Debt/Equity (mrq)

    1.04%

  • Levered Free Cash Flow (ttm)

    -4.4M

Research Analysis: 002332.SZ

View More

Company Insights: 002332.SZ

Research Reports: 002332.SZ

View More

People Also Watch